Category Archives: People

Global Times: Chinese artisan weaves Zhuang brocade into World Cup

Global Times: Guangxi’s Zhuang brocade becomes official FIFA World Cup merchandise, showcasing China’s cultural heritage. Beijing, CHINA, May 30, 2026 (GLOBE NEWSWIRE) — Incorporating elements of Guangxi’s Zhuang brocade into official licensed products for this year’s FIFA World Cup, local artisans have recently been busy creating a range of Zhuang brocade-inspired souvenirs, including footballs, jerseys, […]

Global Times: At 80, award winning illustrator Cai Gao still draws inspiration from childhood

Global Times: Cai Gao, China’s first Hans Christian Andersen Award winner, blends tradition and childhood wonder across 50 years of art. Beijing, CHINA, May 30, 2026 (GLOBE NEWSWIRE) — With silver hair, and a lifetime spent never leaving the world of childhood, 80-year-old Cai Gao, China’s first illustrator to win the Hans Christian Andersen Award, […]

Global Times: China demonstrates remarkable ability to set a long-term vision and actually execute it

Global Times: Expert Chandran Nair sees China’s 15th Five-Year Plan as a global stability anchor, prioritising rural growth and sustainability. Beijing, CHINA, May 30, 2026 (GLOBE NEWSWIRE) — 2026 marks the commencement of China’s 15th Five-Year Plan (2026-30), a pivotal phase in the nation’s medium to long-term development. A successful venture starts with a good […]

Orion Pharma announces first results from Phase 1/2 TEADES trial with TEAD inhibitor ODM-212 in patients with advanced solid tumours

ORION CORPORATION PRESS RELEASE 30 MAY 2026 at 21:30 EEST         Orion Pharma announces first results from Phase 1/2 TEADES trial with TEAD inhibitor ODM-212 in patients with advanced solid tumours Data presented at 2026 ASCO® Annual Meeting show ODM-212 was well tolerated, with proteinuria being the most common treatment related adverse event (TRAE) ODM-212 showed early […]

Eikon Therapeutics Presents Data on Clinical-Stage Programs at the 2026 Annual Meeting of the American Society of Clinical Oncology

TeLuRide-005, a Phase 2 trial of EIK1001 in first-line patients with stage 4 NSCLC completed enrollment of both non-squamous and squamous cohorts and reports updated rates of response and disease control, strengthening the case for continued development Phase 1/2 trial of EIK1003 reports updated safety and efficacy monotherapy data and initial combination data with weekly […]

Global Data for BioNTech and Bristol Myers Squibb’s PD-L1xVEGF-A Bispecific Pumitamig Shows Encouraging Efficacy in Patients with Non-Small Cell Lung Cancer in ROSETTA Lung-02 Trial

First investigational PD-(L)1xVEGF bispecific immunomodulator to present global data showing encouraging efficacy in combination with chemotherapy in first-line non-small cell lung cancer across PD-L1 expression levels and subtypes, highlighting its potential to set a new standard of care Pumitamig plus chemotherapy showed robust and consistent antitumor activity in first-line non-small cell lung cancer at both evaluated dose levels, with higher confirmed objective response rates at the […]

ITM Announces Phase 3 COMPETE Patient-Reported Quality of Life Data with n.c.a. ¹⁷⁷Lu-edotreotide (ITM-11) vs. Everolimus at ASCO 2026

Exploratory analysis showed favorable patient-reported quality of life outcomes and delayed time to deterioration in patients receiving ¹⁷⁷Lu-edotreotide Data build upon previously reported COMPETE efficacy results, adding patient-centered evidence for ¹⁷⁷Lu-edotreotide in GEP-NETs Chicago, Illinois, May 30, 2026 — ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced encouraging Health-Related Quality […]

Mineralys Therapeutics Presents New Data from the Phase 3 Launch-HTN Trial of Lorundrostat in Participants with Hypertension and Chronic Kidney Disease at European Meeting on Hypertension and Cardiovascular Protection (ESH 2026)

– Post hoc analysis from pivotal Launch-HTN trial shows statistically significant and clinically meaningful reductions in blood pressure in participants with chronic kidney disease – – In participants with chronic kidney disease and baseline albuminuria, lorundrostat significantly reduced urine albumin-to-creatinine ratio – – Lorundrostat demonstrated a favorable safety profile in participants with and without chronic […]

Cogent Biosciences Announces Detailed Clinical Data from PEAK Phase 3 Trial with Bezuclastinib in Combination with Sunitinib in Gastrointestinal Stromal Tumors (GIST) at 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

Bezuclastinib combination is first treatment ever to demonstrate statistically significant advantage against active comparator in GIST patients; median PFS of 16.5 months versus 9.2 months (HR=0.50, CI: 0.39-0.65, p<0.0001) for bezuclastinib combination compared to sunitinib alone Bezuclastinib combination provides clear PFS benefit regardless of primary or secondary KIT mutations Mean duration of treatment estimated at […]

Replimune Presents 3-Year Landmark Overall Survival Analysis from IGNYTE Clinical Trial During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting

WOBURN, Mass., May 30, 2026 (GLOBE NEWSWIRE) — Replimune Group, Inc. (NASDAQ: REPL), a clinical-stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today presented 3-year landmark overall survival data from the IGNYTE clinical trial of RP1 plus nivolumab in patients with anti-PD-1 failed melanoma during an oral session at the 2026 American Society […]